To the Editor: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid neoplasms characterized by ineffective hematopoiesis in one or more cell lines and risk of progression to acute myeloid leukemia. According to the International Classification of Diseases-10th Edition (ICD-10) ...
骨髓增生异常综合征理赔 | 骨髓增生异常综合征(Myelodysplastic Syndromes,简称MDS),是起源于造血干细胞的一组异质性髓系克隆性疾病,该病的特点是髓系细胞发育异常,主要表现为无效造血、难治性血细胞减少、高风险向急性髓性白血病(AML)转化2016年WHO发布的《造血与淋巴组织肿瘤分类(2016)》中,MDS的ICD-O编码也全部为...
In 2014, a claims-based prognostic scoring system, the SEER-Medicare MDS Risk Score (SMMRS) was developed to risk-stratify MDS patients for overall survival using ICD9 codes {Uno, 2014}. In 2015, ICD9 codes were replaced by ICD10 codes. In this study, we updated SMMRS with inclusion ...
Hence, it seems logical that with the implementation of the 11th revision of the International Classification of Diseases (ICD-11), all these diagnoses will be officially viewed as cancerous diseases as the previous distinction between malignant neoplasms (myeloid leukemia) and those of unknown ...
we investigated the rates and risks of heart disease-related mortality (HDRM) and cerebrovascular disease-related mortality (CVARM) in myeloid neoplasms that are frequently affected by TET2 mutations: chronic myelomonocytic leukemia (CMML, ~50% TET2- mutated) and myelodysplastic syndromes (MDS, ~25...
Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012;52(10):2131-8.Goldberg SL, Chen E, Sasane M, et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syn- ...
Introduction: The treatment of myelodysplastic syndromes (MDS) changed after the approval of lenalidomide in 2005, and 2 hypomethylating agents (HMA): azacitidine in 2004 and decitabine in 2006. Erythropoietin-stimulating agents (ESA) and reduced intensity conditioning stem cell transplantation (RIC-...
Patients with thalassemia, sickle-cell disease (SCD), and myelodysplastic syndromes (MDS) receiving frequent transfusions require chelation therapy to prevent complications of iron overload. Deferoxamine (DFO) is an effective iron chelator that has been shown to reduce the morbidity and mortality ...
Part 4: Myelodysplastic Syndromes—Treatment of Low-Risk Patients with the 5q Deletion. Hematol. Transfus. Cell Ther. 2018, 40, 274–277. [Google Scholar] [CrossRef] Richard-Carpentier, G.; DeZern, A.E.; Takahashi, K.; Konopleva, M.Y.; Loghavi, S.; Masarova, L.; Alvarado, Y....